Welcome to our dedicated page for Advanced Biomed SEC filings (Ticker: ADVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Advanced Biomed Inc. SEC filings document a Nevada emerging growth company with common stock listed on Nasdaq under ADVB. The filings identify the issuer’s biotechnology focus in precision medicine and advanced diagnostics and record material events affecting its capital structure, listed security and corporate organization.
Recent 8-K and amended 8-K filings cover securities purchase agreements, an equity line of credit, a short-term loan agreement, share issuances, the 1-for-20 reverse stock split and Nasdaq minimum-bid-price correspondence. They also document director and officer changes, material definitive agreements, completed acquisition or disposition activity, amendments to charter documents, and other formal disclosures tied to governance, financing and shareholder rights.
Advanced Biomed Inc. reports that it is terminating a previously established equity purchase arrangement with Helena Global Investment Opportunities I Ltd. The Purchase Agreement, signed on June 6, 2025, had allowed the company, at its discretion, to issue and sell up to $25,000,000 of common stock with a par value of $0.001 per share.
On July 14, 2026, the company delivered a Termination Notice under a contractual provision permitting termination with five trading days’ prior written notice, provided there were no outstanding Advance Notices and all amounts, including all Commitment Fee Shares, had been paid. These conditions were satisfied, and the company states it has not issued or sold any shares to the investor pursuant to any Advance under the agreement other than the Commitment Fee Shares. The termination becomes effective on July 21, 2026.
Advanced Biomed Inc. reported the results of its annual stockholder meeting held on June 30, 2026, where all five proposals passed. Stockholders elected five directors, approved executive compensation on a non-binding basis, and chose annual advisory votes on pay.
Holders of 1,422,573.80 common shares were represented, about 86.105% of the 1,652,133 shares outstanding and entitled to vote as of May 29, 2026, establishing a quorum. Stockholders also ratified WWC, P.C. as auditor for the fiscal year ending June 30, 2026, and approved a potential adjournment of the meeting if needed.
Advanced Biomed Inc. has entered into a material definitive agreement to sell 100% of the issued and outstanding shares of its wholly owned Taiwan subsidiary, Advanced Biomed Inc. (Taiwan), for an aggregate purchase price of US$490,000. This entity conducts the company’s biomedical research and development operations, including the A+PerfusC integrated perfusion 3D cell culture platform.
The buyer is described as an unrelated third party, and the transaction is expected to close within three months from June 30, 2026, subject to conditions in the share purchase agreement. After this disposition, Advanced Biomed plans to continue operating its remaining businesses, including AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited.
Advanced Biomed Inc. is calling a June 30, 2026 in‑person annual meeting in Tainan, Taiwan, asking stockholders to elect five directors, approve a non‑binding say‑on‑pay vote, choose the frequency of future say‑on‑pay votes, ratify auditor WWC, P.C., and permit adjournment if more proxies are needed. Only holders of 1,652,133 common shares outstanding as of May 29, 2026 may vote. The proxy highlights an April 2026 leadership change appointing Xiaomin Chen as Chairman and CEO and the completed acquisition of Acellent Technologies (Hong Kong) Co. Limited, an AI company focused on large language models and trustworthy AI for regulated financial markets. The Board reports three independent directors, established audit, compensation, and nominating committees, adoption of a clawback and insider trading policy, a 1‑for‑20 reverse stock split that restored Nasdaq bid‑price compliance, and a related‑party acquisition where Chen received 270,000 shares at $4.00 per share for Acellent.
Advanced Biomed Inc. reported net income of $5,982,078 for the nine months ended March 31, 2026, driven mainly by a one-time gain of $7,346,684 from selling its Hong Kong subsidiary and related clinical operations. From continuing operations, the company earned $6,254,557 over nine months but posted a quarterly loss of $488,942, reflecting ongoing R&D and administrative costs.
Cash from continuing operations was $2,602,697 at March 31, 2026, with net cash used in operating activities of $1,363,675. Management discloses substantial doubt about the company’s ability to continue as a going concern and highlights reliance on new funding, including a January 2026 private placement raising $248,000 and an equity line facility of up to $25,000,000. The company executed a 1‑for‑20 reverse stock split and had 1,382,133 shares outstanding as of March 31, 2026.
Advanced Biomed Inc. completed the acquisition of Acellent Technologies (Hong Kong) Co. Limited by issuing 270,000 shares of its common stock at $4.00 per share, for an estimated consideration of $1,080,000. The shares were issued under Section 4(a)(2) of the Securities Act.
The company is undertaking a strategic pivot from life sciences to artificial intelligence development. In connection with this change, former CEO and chairman Yi Lu entered into a mutual separation, receiving 39,999 shares of common stock as severance, and Xiaomin Chen was appointed as the new Chief Executive Officer, director and Chairman of the Board with compensation of $12,000 per month.
Advanced Biomed Inc. entered into an unsecured Loan Agreement with Jie Wang under which the lender provided a US$600,000 short-term loan. The loan carries a 10% annual interest rate, runs for six months from the disbursement date, and may be extended once for an additional six months by mutual written agreement.
The company must repay the full US$600,000 principal plus accrued interest on or before the maturity date but can prepay at any time without penalty, with partial prepayments applied first to interest and then principal. Advanced Biomed plans to use the loan proceeds for operations, and the agreement is governed by New York law.
Advanced Biomed Inc. entered into a Share Purchase Agreement to acquire Acellent Technologies (Hong Kong) Co. Limited, which provides AI-powered financial verification and audit solutions. The seller will receive 270,000 shares of Advanced Biomed common stock, valued at $4.00 per share, for an estimated total of $1,080,000.
The acquisition is conditioned on completing financial and legal due diligence of Acellent and obtaining all required regulatory approvals, so the transaction has not yet closed.
Advanced Biomed Inc. reported leadership changes effective March 25, 2026. Steven I-Fang Cheng resigned as both a member of the Board of Directors and as Chief Technology Officer. The company stated that his resignation was not due to any disagreement over operations, policies, or practices.
On the same date, the Board, following a recommendation from the Nominating Committee, appointed Chief Financial Officer Mingze Yin as a director. The company disclosed that Mr. Yin has no family relationships with other leaders, no special arrangements leading to his appointment, and no related-party transactions requiring disclosure.